Lives unaffected by cystic fibrosis

Clinical Trial Finder

Be a part of the movement transforming the future of cystic fibrosis treatment.

Clinical trials are listed below.

  • Anti-InfectiveEnrolling Location: Multiple care centres across the US

    Phase 3 study of inhaled vancomycin in adults and children 6 years and older with cystic fibrosis. , protocol number SAVARA SAV005

    This study is taking place at multiple care centers across the U.S. It will look at the effectiveness of the inhaled drug vancomycin in adults and children 6 years and older with cystic fibrosis and positive cultures for methicillin-resistant Staphylococcus aureus (MRSA).

    • Age:

      6 years and older

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      30-100%

    • Number of Visits:

      8

    • Length of Participation:

      12 months

    Contact us about this clinical Trial >
  • Restore CFTR FunctionClosed to enrollment Location: Multicentre

    A Phase 3 Study of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor , protocol number NCT02412111 VX14-661-109

    This is a Phase 3, randomized, double-blind, ivacaftor-controlled, parallel-group, multicenter study in subjects aged 12 years and older with CF who are heterozygous for the F508del-CFTR mutation and a second CFTR allele with a gating defect that is clinically demonstrated to be ivacaftor responsive.

    • Age:

      12 years and older

    • Mutation(s):

      Heterozygous for F508del-CFTR mutation and a second CFTR allele with a gating defect that is clinically demonstrated to be ivacaftor responsive

    • FEV1% Predicted:

      FEV1 ≥40% and ≤90% of predicted normal for age, sex, and height

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Nutritional-GICompleted with results Location: Multiple care centres across the US

    RESULT: Study of liprotamase non-porcine enzymes , protocol number NCT03051490

    This study evaluated the effectiveness of liprotamase, a non-pig-derived pancreatic enzyme replacement therapy (PERT), as compared to Pancreaze®, a pig-derived PERT.

    • Age:

      7 years and older

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      No FEV1 limit

    • Number of Visits:

      17

    • Length of Participation:

      30 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionCompleted with results Location: Multiple US sites

    Vertex Lumacaftor (VX-809) and Ivacaftor in children with CF aged 6 to 11 years and have two copies of the delF508 CFTR mutation. , protocol number VX13-809-011b

    This was an open-label study designed to look at the safety of lumacaftor in combination with ivacaftor (Orkambi). This study was for younger children with CF who have two copies of the F508del CFTR mutation.

    • Age:

      6-11 years

    • Mutation(s):

      Two copies of F508del

    • FEV1% Predicted:

      No FEV1 limit

    • Number of Visits:

      11

    • Length of Participation:

      27 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionCompleted with results Location: Multiple US sites

    Phase 2 study of VX-152 combination drug in people with cystic fibrosis. , protocol number Vertex VX-152-102

    This study is taking place at multiple care centres accross the US. It will look at the safety and tolerability of the drug VX-152 in combination with both ivacaftor and tezacaftor (VX-661).

    • Age:

      18 years and older

    • Mutation(s):

      homozygous or hetrozygous F508del

    • FEV1% Predicted:

      40 - 90%

    • Number of Visits:

      10

    • Length of Participation:

      16 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Multiple care centres across the US

    Phase 1/2 Study of PTI-801 drug in healthy adults and then in adults with cystic fibrosis. , protocol number Proteostasis Therapeutics NCT03140527 PTI-801-01

    This study is taking place at multiple care centres across the US. It will look at the safety and tolerability of the drug PTI-801

    • Age:

      18 years and over

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      40 - 90%

    • Number of Visits:

      8

    • Length of Participation:

      30

    Contact us about this clinical Trial >
  • Restore CFTR FunctionCompleted with results Location: Multiple US sites

    Phase 3 study of tezacaftor (VX-661) combination drug in children with cystic fibrosis. , protocol number NCT02953314 VERTEX VX15-661-113

    This study evaluated the safety and tolerability of the drug Tezacaftor (VX-661) in combination with ivacaftor (Kalydeco®) in children with CF. This study was for children who have two copies of the F508 del mutation or one copy of F508del and a second mutation that is either residual function or results in a gating defect and responds to ivacaftor.

    • Age:

      6-11 years

    • Mutation(s):

      homozygous or hetrozygous F508del

    • FEV1% Predicted:

      40% or greater

    • Number of Visits:

      9

    • Length of Participation:

      28 weeks

    Contact us about this clinical Trial >
  • ObservationalEnrolling Location: Australia, Melbourne

    Multi Breath Nitrogen Washout (MBNW) as a Measure of Small Airway Function in Patients With Respiratory Disease , protocol number NCT00163696

    Measurements of Inhomogeneity of the Small Airway With Patients With Cystic Fibrosis, Asthma and Bronchiolitis Obliterans Syndrome (Post Transplant) Using the Multi Breath Nitrogen Washout Technique

    • Age:

      18-65 years

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not Specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • OtherActive, not recruiting Location: USA

    Viral pathogenisis of early cystic fibrosis lung disease , protocol number NCT01973192 1R01HL116211-01

    Study will test the hypothesis that early viral infections alter the bacterial flora and inflammatory profile in the airway and accelerate progression of pulmonary disease in infants with cystic fibrosis.

    • Age:

      2-4 months

    • Mutation(s):

      Hetrozygous

    • FEV1% Predicted:

      Not Specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Anti-InfectiveEnrolling Location: USA

    STOP 2: Treatment of pulmonary exacerbations in people with CF , protocol number STOP2-1P-15

    This study is taking place at multiple care centers across the U.S. It will look at the safety and effectivness of different lengths of IV treatment for pulmonary exacerbations in people with CF.

    • Age:

      18 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      25 to 100%

    • Number of Visits:

      3

    • Length of Participation:

      35 days

    Contact us about this clinical Trial >
  • Displaying results 101-110 (of 178)
     |<  <  7 - 8 - 9 - 10 - 11 - 12 - 13 - 14 - 15 - 16  >  >|